A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Clinical trial NCT05500222 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05500222
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-26
- Primary completion
- 2026-12-01
- Enrollment
- 845
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.